Is Saccharomyces boulardii worth it?
Saccharomyces boulardii is one of the more defensible probiotic choices, but it is still a use-case supplement, not a generic gut-health badge. The strongest practical case is short-term, strain-labeled use around antibiotic-associated diarrhea risk; vague high-CFU probiotic blends are a different product and do not inherit the evidence.
The call
The evidence is not a blanket endorsement of probiotics; it is strain- and indication-specific. AGA guidance lists S. boulardii among suggested probiotic options for adults and children on antibiotics in a C. difficile risk-reduction context, while recommending probiotics only in a clinical-trial context for several other GI conditions. Meta-analyses of S. boulardii report lower antibiotic-associated diarrhea incidence, but products, doses, populations, and baseline risk vary. This earns a mixed keep verdict for short-term, risk-matched use, not for daily microbiome restoration marketing.
Safety
Avoid casual use in severely immunocompromised people, critically ill patients, premature infants, people with central venous catheters, short-bowel risk, or recent major surgery unless a clinician is supervising. S. boulardii is a live yeast, and rare bloodstream or catheter-associated fungal infections have been reported in high-risk settings. Gas, bloating, constipation, thirst, or stool changes can occur. Stop and seek medical care for fever, bloody diarrhea, severe abdominal pain, dehydration, or diarrhea that persists or worsens rather than escalating the probiotic dose.
Dose that matters: Common studied use is 250-500 mg once or twice daily, often labeled around 5-10 billion CFU/day, started with antibiotics and continued briefly after the course. Prefer a product that names S. boulardii and, when possible, the studied CNCM I-745/CBS 5926 strain; do not substitute an unnamed yeast/probiotic blend.
Sources
Tier 1 · evidence synthesis · Reviewed by the Stack-kit desk